Missed Opportunities on Emergency Remdesivir Use
Open Access
- 28 July 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (4), 331-332
- https://doi.org/10.1001/jama.2020.11932
Abstract
This Viewpoint argues that the FDA’s Emergency Use Authorization (EUA) of remdesivir missed important opportunities to mandate further study of the drug’s safetThis publication has 8 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- A Proposed Lottery System to Allocate Scarce COVID-19 MedicationsJAMA, 2020
- Emergency Use Authorization of RemdesivirJAMA, 2020
- A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 PandemicJAMA, 2020
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19ACS Central Science, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Mitigating Health Risks of Prescription DrugsJAMA, 2019